Keeping aside the role of IL-1β protein as a potential therapeutic target for dry eye disease and COVID-19, its inhibitors have also been implicated to have a central role in the treatment of myeloma, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), etc. [27,28,29,30]. The gene discussed is IL1B; the disease is amyotrophic lateral sclerosis.